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OBJECTIVE — The purpose of this study was to test the hypothesis that changing utilization
of lipid-lowering, antihypertensive, and oral hypoglycemic drugs may be associated with trends
in all-cause mortality in men and women with type 2 diabetes.
RESEARCH DESIGN AND METHODS — This was a cohort study in 197 general
practices in the U.K. General Practice Research Database including 48,579 subjects with type 2
diabetes ﬁrst diagnosed between 1996 and 2006. Measures included all-cause mortality and
prescription of hypoglycemic, lipid-lowering, and antihypertensive drugs.
RESULTS — From 1996 to 2006, incidence of type 2 diabetes increased and the mean age at
diagnosis declined in women. Prescription of statins within 12 months of diagnosis increased
(1996, women 4.9%, men 5.1%; 2005, women 63.5%, men 71.0%), as did drugs acting on the
renin-angiotensinsystem(1996,women19.4%,men21.5%;2005,women45.5%,men54.6%)
and metformin (1996, women 19.1%, men 15.8%; 2005, women 45.5%, men 42.8%), whereas
prescription of sulfonylureas declined. All-cause mortality in the ﬁrst 24 months after diabetes
diagnosisdeclinedinmenfrom47.9per1,000person-yearsforsubjectswithdiabetesdiagnosed
in 1996 to 25.2 for subjects with diabetes diagnosed in 2006 and in women from 37.4 in 1996
to 27.6 in 2006. In a multiple regression model adjusting for age and comorbidity, prescription
of statins before or after diagnosis, renin-angiotensin system drugs before or after diagnosis, and
metformin after diagnosis were associated with lower mortality.
CONCLUSIONS — Widespread implementation of more effective prescribing to control
lipids, blood glucose, and blood pressure may have contributed to recent declines in early
mortality in men and women with type 2 diabetes.
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T
he epidemiology of type 2 diabetes
is changing. The prevalence of diag-
noseddiabeteshasincreasedrapidly
in national health survey data from a
number of countries including the U.S.
and the U.K. (1,2). Epidemiological stud-
ies also showed that the incidence of type
2 diabetes is increasing (3). This increas-
ing frequency of type 2 diabetes has been
associated with increased occurrence of
diabetes at younger ages, with some stud-
iessuggestingadeclineinthemeanageat
diagnosis of diabetes in the U.S. (4).
At the same time, evidence has accu-
mulated for the potential effectiveness of
cholesterol-lowering therapy with statin
drugs (5,6) and antihypertensive therapy
(7), especially with drugs acting on the
renin-angiotensin system (RAS) (8), for
reducing cardiovascular events and mor-
tality in type 2 diabetes. When good
bloodglucosecontrolisachieved,oralhy-
poglycemic therapy reduces diabetes-
related end points (9). Therapy with
metformin has been speciﬁcally associ-
ated with reduced all-cause mortality in
diabetes (10). In the UK Prospective Dia-
betes Study, therapy with sulfonylurea
drugs was not associated with increased
mortality compared with insulin therapy
(9), but several nonrandomized studies
have associated sulfonylurea drugs with
increased mortality compared with met-
formin (11,12).
The aim of the present study was to
analyze the signiﬁcance of these develop-
ments for the prognosis of patients with
newly diagnosed type 2 diabetes. We
aimed to evaluate the extent and time
course of changes in use of statins, anti-
hypertensive drugs, and oral hypoglyce-
mic drugs among patients with type 2
diabetes and to determine whether
changes in drug usage are associated with
changes in early mortality in men and
women with type 2 diabetes.
RESEARCH DESIGN AND
METHODS— We analyzed data from
the U.K. General Practice Research Data-
base (GPRD), a large database including
electronic patient records for 5% of
U.K. family practices (13). In the U.K.,
there is population-based provision of
primary care with 98% of the population
being registered with a family practice.
The quality of GPRD data has been eval-
uated in several studies (13).
The present longitudinal study in-
cluded all 197 family practices, with a
registered population of 1.63 million,
that contributed data to GPRD continu-
ously between 1995 and 2006. We se-
lected the population aged 30 years
becausetype1andtype2diabetesareless
readily distinguished at younger ages. In-
dividuals with prevalent diabetes were
identiﬁed from the electronic clinical
record if they ever had the diagnosis of
diabetes or were given a prescription for
oral hypoglycemic drugs or insulin. The
dateofdiagnosiswasidentiﬁedastheear-
lier of the ﬁrst medical diagnosis for dia-
betes or the ﬁrst medical prescription for
hypoglycemic drugs, and only subjects
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January 1996 and 31 December 2006
were included. Of these, 93.6% were
identiﬁed with diagnostic codes and only
6.4% were initially identiﬁed with ther-
apycodesonly.Therewere399of22,997
(1.7%) women ﬁrst diagnosed with codes
associated with “diabetes in pregnancy,”
but there was no increase in this propor-
tion over the time of study. All subjects
had a minimum period of 12 months of
records before the diabetes diagnosis
date. Subjects who were ever diagnosed
with type 1 diabetes or who were given
prescriptions for insulin within 6 months
of diagnosis were excluded as cases of
type 1 diabetes. Prevalent cases were ex-
cluded because both therapy and hazards
vary with duration of diabetes.
Analysis
Age-speciﬁc incidence rates for type 2 di-
abetes were estimated using the number
ofincidentcasesasthenumeratorandthe
registered person-years at risk as the de-
nominator. Age-standardized rates were
estimated using the European Standard
Population for reference. The mean age at
diagnosisandtheproportionofdiagnoses
that were at ages 30–44 were also esti-
mated. Trends by study year were esti-
matedbylinearregressionusingmeansor
proportions as observations.
Thecharacteristicsofsubjectsatdiag-
nosis were evaluated including whether
coronaryheartdisease(CHD)(13),stroke
(13),orrenaldisease(includinganymen-
tionofadiagnosisassociatedwiththekid-
ney) was ever diagnosed before the
diagnosis of diabetes using appropriate
medical codes (13). Drug prescriptions
were analyzed by mapping drug codes to
chapter subheadings in the British Na-
tional Formulary (14). We analyzed
whether statins or antihypertensive drugs
were ever prescribed before diagnosis of
diabetes, with drugs acting on the RAS as
a separate class. Antihypertensive drugs
included ACE inhibitors, adrenergic neu-
roninhibitingdrugs,angiotensinIIrecep-
torblockers,-blockers,calciumchannel
antagonists, centrally acting drugs, thia-
zideandpotassium-sparingdiuretics,and
vasodilators. Oral hypoglycemic drugs
were grouped into metformin and sulfo-
nylureadrugs.Toanalyzedrugutilization
after the diagnosis of diabetes while tak-
ing into account both calendar time and
the duration of the diabetic illness, sub-
jects were grouped by year of diagnosis.
Then for each cohort deﬁned by year of
diagnosis, prescriptions were analyzed by
year after the diagnosis of diabetes.
Mortality from all causes was esti-
mated using the death records within the
GPRD. To compare mortality of patients
withdiabetesdiagnosedindifferentyears,
only the ﬁrst 2 years after diagnosis were
considered. This was because duration of
follow-up was longer for earlier years of
study, but mortality varies with diabetes
duration.Toavoidconfoundingofyearof
diagnosis with diabetes duration, analy-
ses were restricted to the ﬁrst 2 years after
diagnosis. Mortality rates were estimated
per 1,000 person-years of follow-up for
men and women with diabetes and were
standardized to the sample distribution
for 2001 as reference. To adjust for ex-
planatory variables, Cox proportional
hazards models were ﬁtted with date of
diabetesdiagnosisasthestartdateandthe
earliest of the date of death or 24 months
after diagnosis or the end of the patient’s
record as the end date. Explanatory vari-
ables were year of diagnosis, age, preva-
lent CHD, stroke and renal disease, use of
statins, antihypertensive therapy, and
RAS drugs before diagnosis and prescrib-
ing of metformin, sulfonylurea drugs,
statins, antihypertensive drugs, or RAS
drugs after diagnosis. Robust SEMs were
estimated to allow for clustering by prac-
tice. Because drug treatment after diagno-
sis varied over time, utilization of each
drug was also ﬁtted separately as a time-
dependent covariate, with adjustment for
prediagnosis events. Estimates from the
two models were compared.
RESULTS— In the registered popula-
tion aged 30 years, there were 953,223
person-yearsin1996,risingto1,048,067
in 2006. The proportion of registered
subjects aged 30–44 years was 35% in
1996 and 34% in 2006. The female-to-
male sex ratio was 1.08 in 1996 and 1.05
in 2006. There were 29,068 prevalent
cases of diagnosed diabetes in 1996 and
62,455 in 2006. There were 2,636 inci-
dent cases of type 2 diabetes in 1996 and
Table 1—Trends in type 2 diabetes incidence, mean age at diagnosis of diabetes, and comorbidity and drug utilization at diagnosis by year of
diagnosis
Year of
diagnosis
Diabetes incidence 30 years
(rate per 1,000 person-years)*
Age (years) at ﬁrst diabetes
diagnosis†
Proportion (%) of
all new diagnoses
in those aged
30–44 years
Prevalent CHD at
diagnosis
Women Men Women Men Women Men Women Men
1996 2.23  0.07 3.00  0.08 66.1  13.4 62.5  12.2 7.5 7.9 17.2 19.6
1997 2.29  0.07 3.07  0.08 65.5  13.8 62.3  12.1 8.6 7.9 15.9 19.9
1998 2.36  0.07 3.39  0.08 65.3  14.3 62.1  12.5 9.4 9.5 16.4 21.0
1999 2.66  0.07 3.66  0.09 65.3  14.2 62.5  12.1 9.3 7.6 16.5 22.9
2000 3.50  0.08 4.58  0.10 64.6  14.5 62.3  12.1 10.9 7.9 17.8 22.1
2001 3.83  0.09 5.24  0.10 64.1  14.3 62.1  12.2 11.0 8.5 17.0 22.8
2002 4.31  0.09 5.63  0.11 63.6  14.7 62.0  12.2 12.8 8.8 16.2 23.8
2003 4.62  0.09 5.65  0.11 63.0  14.6 62.0  12.5 13.4 9.2 17.2 21.7
2004 4.99  0.10 5.81  0.11 63.3  15.1 62.8  12.5 13.6 8.1 16.9 23.3
2005 4.71  0.09 5.54  0.10 62.9  15.6 62.0  12.3 15.7 9.3 14.2 21.3
2006 4.37  0.09 5.24  0.10 62.5  15.3 62.0  12.4 15.8 9.2 14.0 19.9
P value‡ 0.001 0.001 0.001 0.330 0.001 0.097 0.089 0.414
Data are percentage of subjects in whom diabetes was diagnosed in year except where indicated. *Age standardized to European Standard Population. Data are
means  SEM. †Data are means  SD. ‡Test for linear trend by year.
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newly diagnosed diabetes in total be-
tween 1996 and 2006.
Table 1 shows age-standardized type
2 diabetes incidence rates for men and
women by study year. The incidence of
new diagnoses of type 2 diabetes in-
creased in women from 2.23 per 1,000 in
1996 to 4.37 per 1,000 in 2006. In men,
the increase was from 3.00 per 1,000 in
1996 to 5.24 per 1,000 in 2006. The
mean age at ﬁrst diagnosis of diabetes de-
creased in women from 66.1 years in
1996 to 62.5 years in 2006, but there was
no trend in men (Table 1). The propor-
tion of incident diabetes diagnoses in the
30- to 44-year age-group increased in
women from 7.5% in 1996 to 15.8% in
2006.
Table 1 also shows comorbidity and
coprescribing in subjects with newly di-
agnosed type 2 diabetes by year of diag-
nosis. Approximately 16% of women and
22% of men had prevalent CHD at diag-
nosis,whereas4%ofwomenand5%of
men had prevalent stroke. There was
weak evidence of a decreasing trend in
prevalentCHDandstrokeinwomen.The
proportion of subjects for whom statins
were prescribed before the date of diag-
nosis increased from 2% in both men and
women in 1996 to 32% in women and
37% in men in 2006. The prescription of
antihypertensive drugs before diagnosis
increasedovertime,moreinmen,andthe
increase was especially marked for the
prescription of RAS drugs.
Figure 1 shows trends in drug utiliza-
tion by patients with type 2 diabetes by
yearofdiagnosisanddurationofdiabetes.
Figure 1—Trends in drug utilization by patients with type 2 diabetes by year of diagnosis and
duration of diabetes. Solid lines connect values for patients diagnosed in the same year and with
data points representing increasing durations of diabetes. A: Men. B: Women.
Table 1—Continued
Prevalent stroke
at diagnosis
Prevalent renal
disease before
diagnosis
Prescribed statins
before diagnosis
Prescribed other
hypertensives before
diagnosis
Prescribed RAS before
diagnosis
Women Men Women Men Women Men Women Men Women Men
6.1 5.4 3.7 5.1 1.9 2.2 58.9 44.0 13.2 13.9
4.9 5.1 3.0 5.8 3.5 4.3 61.5 41.9 16.5 15.4
4.2 4.6 3.1 6.0 5.0 6.4 60.8 44.8 17.8 17.3
4.6 5.9 2.3 5.2 8.1 9.9 63.4 50.9 19.6 19.6
5.2 4.7 3.2 6.0 10.5 13.6 64.0 50.8 21.7 20.9
4.1 4.0 3.3 5.6 14.0 15.8 65.4 53.9 24.4 24.2
4.0 4.6 3.2 5.5 14.8 20.8 66.8 56.5 27.4 26.9
3.7 5.0 2.9 6.5 19.5 25.0 68.1 58.1 29.6 29.5
4.6 5.4 3.0 6.2 24.5 30.1 69.2 61.2 30.7 33.0
3.8 4.8 3.3 6.5 27.6 33.5 67.0 59.3 33.1 34.4
3.8 4.2 3.9 6.9 31.5 36.8 65.6 59.7 34.4 36.3
0.011 0.271 0.508 0.005 0.001 0.001 0.001 0.001 0.001 0.001
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drugs, and drugs acting on the RAS show
a cohort effect, increasing as the duration
of diabetes increases. However, utiliza-
tion of metformin and RAS drugs in-
creased for successive years of diagnosis,
whereas utilization of sulfonylurea drugs
declined. Utilization of statins only
showed a period effect with increasing
utilization over time independent of du-
ration of diabetes. There were very large
increases in prescribing of statins, met-
formin,andRASdrugsduringtheperiod.
Prescription of statins within 12 months
of diagnosis increased (1996, women
4.9%, men 5.1%; 2005, women 63.5%,
men 71.0%) as did prescription of drugs
acting on the RAS (1996, women 19.4%,
men 21.5%; 2005, women 45.5%, men
54.6%) and metformin (1996, women
19.1%, men 15.8%; 2005, women
45.5%, men 42.8%), whereas prescrip-
tion of sulfonylureas declined (1996,
women 32.8%, men 34.3%; 2005, women
12.5%, men 14.1%). Utilization of insulin
and other oral hypoglycemic drugs, includ-
ing glitazones, increased during the period,
but they were used by fewer than 10% of
subjects within 2 years of diagnosis. Note
that mortality analyses only included the
ﬁrst 2 years after diagnosis.
Table 2 shows changes in all-cause
mortality in men and women in the ﬁrst 2
years after diagnosis of diabetes in sub-
jects aged 30 years. In men, the relative
decrease in mortality was 47% over the
period, whereas in women, in whom ab-
solute mortality was lower, the relative
decline over the period was 26%.
In the proportional hazards model
(Table3),highermortalitywasassociated
with older age and prevalent CHD,
stroke, or renal disease. Prescription of
statin drugs before or after diabetes diag-
nosis, prescription of drugs acting on the
RAS before or after diagnosis, and pre-
scription of metformin after diagnosis
were associated with lower mortality and
accounted for the association of year of
diagnosis with mortality. After adjust-
ment, increasing year of diagnosis was
positivelyassociatedwithmortality,butthe
signiﬁcance of this ﬁnding is unclear. Haz-
ard ratios (HRs) were generally similar for
men and women, but HRs associated with
prevalent CHD and stroke appeared to be
higher for men, whereas the HR associated
with prevalent renal disease was slightly
higher in women. Fitting drug classes pre-
scribedafterdiagnosisseparatelyastimede-
pendentcovariatesgenerallyledtoasimilar
interpretation.
CONCLUSIONS — Over the past 10
years there has been a substantial reduc-
tion in early mortality of type 2 diabetic
patients within the ﬁrst 2 years after diag-
nosis. Variables that may explain this de-
clineinmortalityincludeadecreaseinthe
ageatdiagnosisinwomenandaslightfall
in the proportion of women who have
cardiovascular disease including CHD
and stroke at diagnosis. Even allowing for
case mix, there is evidence that a rapid
increase in the proportion of men and
Table 2—Age-standardized rates for mortality within 2 years of diabetes diagnosis by year of
diagnosis
Year of
diagnosis
Deaths (person-years)
Age-standardized mortality
(per 1,000 person-years)
within 24 months of
diagnosis*
Women Men Women Men
1996 101 (2,387) 127 (2,637) 37.4 47.9
1997 107 (2,437) 105 (2,749) 40.7 37.7
1998 118 (2,558) 148 (3,055) 41.0 49.7
1999 134 (2,923) 129 (3,413) 40.7 37.6
2000 153 (3,838) 151 (4,326) 37.1 34.5
2001 166 (4,134) 158 (5,009) 39.9 31.5
2002 123 (4,792) 176 (5,458) 25.3 32.2
2003 147 (5,099) 158 (5,595) 30.7 28.1
2004 171 (5,675) 167 (5,918) 30.1 26.2
2005 118 (4,526) 131 (4,780) 25.9 27.2
2006* 48 (1,751) 50 (1,906) 27.6 25.2
P value† 0.002 0.001
Rates were standardized to the sample distribution for 2001 for reference. *Two-year follow-up incomplete.
†Test for linear trend.
Table 3—Variables associated with mortality in ﬁrst 2 years after diabetes diagnosis for men and women
Women: HR (95% CI) P value Men: HR (95% CI) P value
Year of diagnosis (per year) 1.04 (1.02–1.06) 0.001 1.02 (1.00–1.04) 0.113
Age (per year) 1.073 (1.067–1.078) 0.001 1.071 (1.066–1.076) 0.001
Prevalent CHD at diagnosis 1.15 (1.00–1.32) 0.044 1.25 (1.10–1.43) 0.001
Prevalent stroke at diagnosis 1.38 (1.13–1.69) 0.002 1.71 (1.48–2.00) 0.001
Prevalent renal diseases at diagnosis 1.58 (1.25–1.99) 0.001 1.19 (0.98–1.44) 0.071
Statin use before diagnosis 0.52 (0.43–0.63) 0.001 0.56 (0.48–0.65) 0.001
Statins prescribed after diagnosis* 0.29 (0.24–0.35) 0.001 0.34 (0.29–0.40) 0.001
RAS drugs before diagnosis 0.85 (0.75–0.96) 0.007 0.90 (0.78–1.05) 0.171
RAS drugs prescribed after diagnosis* 0.45 (0.37–0.55) 0.001 0.56 (0.47–0.66) 0.001
Other antihypertensive treatment before diagnosis 0.91 (0.80–1.04) 0.158 1.18 (1.03–1.34) 0.016
Other antihypertensive prescribed after diagnosis* 0.83 (0.62–1.10) 0.206 0.86 (0.68–1.09) 0.218
Metformin prescribed after diagnosis* 0.70 (0.60–0.80) 0.001 0.61 (0.54–0.68) 0.001
Sulfonylurea drugs prescribed after diagnosis* 1.44 (1.27–1.64) 0.001 1.60 (1.43–1.78) 0.001
Insulin prescribed after diagnosis* 1.20 (0.68–2.10) 0.527 1.48 (0.92–2.36) 0.103
HRs were adjusted for each of the variables shown. *Within 2 years of diagnosis.
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ready taking statin drugs may be associ-
ated with lower mortality. Changing
patternsofdrugutilizationafterdiagnosis
of diabetes, including increased use of st-
atins and metformin and decreased use of
sulfonylurea drugs, may also be associ-
ated with lower mortality. These observa-
tions must be interpreted with caution as
confounding by indication is generally
importantinnonrandomizedstudies,and
the effects may be difﬁcult to anticipate.
The role of unmeasured risk factors such
as cigarette smoking must also be consid-
ered. Earlier diagnosis may be contribut-
ing to increasing prevalence and could
also contribute to declining mortality in
clinicaldiabetesconsistentwithlead-time
bias. This effect might be important for
early mortality, whereas changes in drug
utilization after diagnosis may be more
relevant for later mortality after the ﬁrst 2
years. Nevertheless, these analyses pro-
vide suggestive evidence that widespread
implementation of preventive medical
care both before and after the time of di-
agnosis may be contributing to the im-
proving prognosis of type 2 diabetes.
Trends in drug utilization were generally
similar in men and women, but the de-
cline in mortality was greater in men in
whom absolute mortality rates were
higher.
Comparison with other studies
The present observations must be set in
the context of long-term declining trends
in risk factors, such as smoking (15), as
well as declining cardiovascular mortality
in the general population (16). A number
of studies have evaluated trends in all-
cause mortality, cardiovascular mortality,
andincidentcardiovasculareventsintype
2 diabetes (17–22). Reports from
Dundee, Scotland, from 1993 to 2004
(17) and Ontario, Canada, from 1992 to
2000 (18) show declining all-cause mor-
tality in diabetic populations. These ﬁnd-
ings are consistent with a report from
Rochester,Minnesota,whichshowedthat
between 1970 and 1994 mortality de-
clined in diabetic subjects, although this
declinewassmallerthanthemortalityde-
crease observed in the nondiabetic popu-
lation (19). Data from Ontario (17) and
from the Framingham study (20) also
demonstrate declining incidence of new
cardiovascular events. However, there is
evidence that trends may differ for men
and women. Data from the U.S. National
HealthandNutritionExaminationSurvey
show that mortality of diabetic men de-
clined between 1971 and 2000 (21,22).
In women with diabetes, mortality ini-
tially increased (21) and then later
showed no decline up to 2000 (22). Our
results up to 2006 suggest that mortality
in female as well as male diabetic patients
is now declining. All-cause mortality in
the general population has declined dur-
ing this period, and further research is re-
quired to evaluate trends in relative
mortality in patients with type 2 diabetes.
It would also be desirable to evaluate
cause-speciﬁc mortality. Analysis of
GPRD data allows us to link individual
patient survival data to information con-
cerning comorbidity and prescribing. Re-
sults from these analyses show that across
the diabetic population there have been
major changes in drug utilization during
this period, and these changes are associ-
ated with differences in mortality risk. In
particular, utilization of statins either be-
fore or after diabetes diagnosis and use of
metforminratherthansulfonylureadrugs
after diagnosis may be associated with
lower mortality risk.
Strengths and limitations
The validity of GPRD data has been dem-
onstrated in several studies. In particular,
Shah and Martinez (23) reported that
mortalityratesestimatedfromGPRDdata
were comparable to those observed in the
U.K. general population. Mulnier et al.
(24) reported a mortality rate for individ-
uals with prevalent cases of diabetes in
GPRD of 60.2 per 1,000 patient-years,
which is higher than the rate we reported
for individuals with incident cases of dia-
beteswithshortdurations.Thevalidityof
clinical event data in GPRD has been
shown to be good (13). However, causes
of death were not readily available for
analysis and cause-speciﬁc mortality was
not estimated. Clinical information for
measures including smoking, blood pres-
sure, cholesterol, and A1C is included in
the GPRD, but there were secular trends
in recording in the present period that
wouldcomplicateinterpretation.Classiﬁ-
cation of drug prescribing was based on
oneormoreprescriptions,butinterpreta-
tiondidnotdifferiftwoormoreprescrip-
tions were used. Drug combinations were
not explicitly modeled.
Although overall data for mortality
can be viewed with conﬁdence, in this
nonrandomized study, associations iden-
tiﬁedmaybeexplainedbyunmeasuredor
misclassiﬁed confounders. When unmea-
sured and imprecisely measured con-
founding is present, associations may be
incorrectly ascribed to more precisely
measured exposures such as drug utiliza-
tion. We caution that the results should
not be used to estimate the beneﬁts or
harms of particular therapies. Rather, the
present results suggest that ﬁndings from
randomized clinical trials may hold in the
general population and contribute to im-
proving survival trends. Combinations of
these interventions may be particularly
beneﬁcial (25).
In summary, mortality of men and
women with newly diagnosed type 2 dia-
betes has declined between 1996 and
2006. Widespread use of statins before
and after diagnosis and use of metformin
rather than sulfonylurea drugs after diag-
nosis may be associated with improving
mortality trends.
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